Veos operates under a governance framework designed for clarity, accountability, and the durability of long-term scientific and commercial value.
Good governance is not bureaucracy — it is the operating system that makes durable performance possible. At Veos, governance lives in our decision rights, our financial controls, and the rigor with which we evaluate every scientific and commercial decision.
Our framework is built on four pillars: corporate structure, scientific integrity, financial discipline, and regulatory compliance. Each pillar is reviewed continuously and tightened as the company scales.
Veos Pharmaceuticals, S.L. is incorporated in Spain (CIF: B10704534) and operates under the country's Sociedad Limitada framework. The company is co-founded on a balanced equity structure that aligns founder incentives with long-term value creation.
Solidary administrators hold decision rights documented in our articles of incorporation, with material decisions subject to founder review.
Every commercial claim traces back to a primary data source — peer-reviewed publication, published clinical trial, or controlled internal validation. We do not market claims we cannot defend.
External scientific advisors review platform decisions, formulation work, and trial design across human health, agriculture, and environmental programs.
Veos has been profitable since 2024. The company operates without dilutive outside capital, funding growth through revenue and selective debt financing where appropriate.
Audited financials are produced annually in compliance with Spanish PGC and IAS standards. Capitalization of intangible assets, IP valuation, and R&D expense recognition follow conservative accounting principles.
Products are developed for compliance with applicable EU, FDA, Health Canada, and national regulatory frameworks. We maintain active monitoring of regulatory change across our markets.
Intellectual property is filed, prosecuted, and defended across the United States, the European Union, and selected international jurisdictions.
Trial data, formulation records, and manufacturing batch information are maintained under controlled documentation systems with audit trails.
Product registrations, GRAS submissions, and EU/national notifications are filed and maintained across all active commercial markets.
Manufacturing partners operate under GMP standards with batch-level testing, traceability, and stability protocols.